Open-Label CDCA 250 mg TID: Clinical Trials

1 completed. 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	1	Completed 1

Follow Open-Label CDCA 250 mg TID: new trials by email Literature Review of Open-Label CDCA 250 mg TID trials Research Report on Open-Label CDCA 250 mg TID

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) Blinded CDCA 250 mg TID, Placebo, Open-Label CDCA 250 mg TID - CTX	Phase 3	Completed	Mirum Pharmaceuticals, Inc.	19	2020-01-31	2024-10-28

Conditions studied

Xanthomatosis, Cerebrotendinous (1)

Sponsors

Mirum Pharmaceuticals, Inc. (1)

Countries

Brazil (1)  ·  United States (1)